Immunohistochemistry staining of GLI1, METTL3/14, and IGF2BP2 also confirmed that inhibitors against GLI1 or METTL3 decreased protein levels of GLI1, METTL3/14, and IGF2BP2 in tumor samples (Fig. 7C). This evidence concerns the gene GLI1 and neoplasm.